Takeda Pharmaceutical (TAK) Stock Price & Analysis

TAK$21.41—
Drug Manufacturers - Specialty & GenericLarge CapGrowth Stock
Compare
Market cap$69.55BEnterprise value—Revenue (TTM)—Market positionTop 25%

Score

53
Neutral
Value
53
Quality
47
Growth
60

AI Analysis

Snapshot

Takeda Pharmaceutical is a mixed profile at 53/100 — Value 53, Growth 60, Quality 47. Under the hood: P/E 28.5, about 20% below its own multi-year median, plus revenue compounding ~4% annually over recent years.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

53
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

60
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

47
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Takeda Pharmaceutical Company Limited (TAK) last printed $21.41. Equity value is $69.55B. Trailing earnings multiple 28.48. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$1.73T$1.77T$2.1T$3.29T$3.2T$3.57T$4.03T$4.26T$4.58T$4.51T

About

Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreements, research partnerships, and strategic alliances with a diverse array of organizations, including academic institutions like the University of Texas MD Anderson Cancer Center and biotech firms such as Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals Inc. Established in 1781, the company maintains its headquarters in Tokyo, Japan.

Takeda Pharmaceutical (TAK) Stock Price & Analysis

TAK price $21.41 —

Ticker
TAK
Price
$21.41
Change
—
Market cap
$69.55B
P/E
28.48
Dividend yield
2.90%
Beta
0.09
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stocklytics score
53
Value
53
Quality
47
Growth
60

Stocklytics score rationale: value 53, quality 47, growth 60.

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener